Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

loss of exclusivity

- PMLiVE

Pfizer’s RA drug tofacitinib tops methotrexate in phase III

Trial results back drug as major new treatment in rheumatoid arthritis

Pfizer forms branded generics sales alliance in China

Forms joint venture with local company Hisun

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

- PMLiVE

Pfizer’s Andrew Thomas takes up UK comms agency role

Joins London-based Red Door Communications as head of international

Pfizer gets US approval for leukaemia drug Bosulif

FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

AstraZeneca and BGT shelve experimental sepsis drug

Decision follows CytoFab’s poor mid-stage clinical trial results

- PMLiVE

End of the line for intravenous bapineuzumab in Alzheimer’s

Negative trial results for Pfizer and Johnson & Johnson to concede defeat

- PMLiVE

Pfizer sells Kent R&D centre to property consortium

Discovery Park Ltd takes over site 18 months after US pharma firm announced plans to exit it

- PMLiVE

Interview: Dan Mathews on pharma marketing trends and the PMEA programme

The chair of judges for PMEA 2012 examines the current and future challenges for the sector

Interview: Dan Mathews on pharma marketing trends and the PMEA programme

The chair of judges for PMEA 2012 examines the current and future challenges for the sector

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links